W
WAVEMAN · COMPANY
AZTR · Azitra, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

AZTR

Azitra, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001701478
ACTIVIST 13D☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
13
13F, latest reported quarter
REVENUE GROWTH
-100.0%
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
1
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
13 funds added or opened last quarter
below 78% of Pharma & Biotech
REVENUE
-100.0% year over year
the lowest in Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
0.3% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
below 83% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Salva Francisco D. disclosed a 5%+ stake (9.99%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -81.5%
-81.5%12M
-87%-58%-29%+1%2025-092025-102025-122026-032026-052026-072026-09 2026-06-24 · Salva Francisco D. filed a 5%+ stake (9.99%)
13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows 13 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Azitra, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Staskey Norm
Chief Financial Officer
BUY
2024-03-29
47,600.0
$10.0K
Whitfill Travis
Chief Operating Officer
BUY
2024-02-13
15,000.0
$4.5K
Staskey Norm
Chief Financial Officer
BUY
2024-02-13
3,300.0
$990
Salva Francisco D.
President and CEO
BUY
2024-02-13
333,300.0
$100.0K
Cavu Advisors, LLC
SELL
2023-06-21
77,953.0
-
22 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 17 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Stonepine Capital Management, LLC
87,083,029.0 sh
$8.9M
Dauntless Investment Group, LLC
11,292,186.0 sh
$1.9M
Nantahala Capital Management, LLC
4,427,226.0 sh
$742.9K
JANE STREET GROUP, LLC
248,433.0 sh
$41.7K
GEODE CAPITAL MANAGEMENT, LLC
95,409.0 sh
$16.0K
5%+ owners
13D = intent to influence · 13G = passive
Salva Francisco D.
ACTIVIST 13D · 2026-06-24
9.99%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$13.0K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$468 POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
2
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$0$7.5K$686.0K$284.0K
OPERATING INCOME$-11.0M$-11.0M$-7.5M$-9.5M
NET INCOME$-11.0M$-9.0M$-11.3M$-10.7M
EPS (DILUTED)-2.25-15.70-54.98-12.74
OPERATING CASH FLOW$-11.2M$-10.2M$-7.4M$-8.3M
CASH$2.1M$4.6M$1.8M$3.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →